Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
Publication
, Journal Article
Becker, A; Eichelberg, C; Sun, M
Published in: Cancer
June 1, 2015
Duke Scholars
Published In
Cancer
DOI
EISSN
1097-0142
Publication Date
June 1, 2015
Volume
121
Issue
11
Start / End Page
1906 / 1907
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Male
- Kidney Neoplasms
- Interferon-alpha
- Humans
- Female
- Carcinoma, Renal Cell
- Antineoplastic Combined Chemotherapy Protocols
- 4206 Public health
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Becker, A., Eichelberg, C., & Sun, M. (2015). Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer, 121(11), 1906–1907. https://doi.org/10.1002/cncr.29255
Becker, Andreas, Christian Eichelberg, and Maxine Sun. “Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?” Cancer 121, no. 11 (June 1, 2015): 1906–7. https://doi.org/10.1002/cncr.29255.
Becker A, Eichelberg C, Sun M. Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 1;121(11):1906–7.
Becker, Andreas, et al. “Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?” Cancer, vol. 121, no. 11, June 2015, pp. 1906–07. Pubmed, doi:10.1002/cncr.29255.
Becker A, Eichelberg C, Sun M. Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 1;121(11):1906–1907.
Published In
Cancer
DOI
EISSN
1097-0142
Publication Date
June 1, 2015
Volume
121
Issue
11
Start / End Page
1906 / 1907
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Male
- Kidney Neoplasms
- Interferon-alpha
- Humans
- Female
- Carcinoma, Renal Cell
- Antineoplastic Combined Chemotherapy Protocols
- 4206 Public health
- 3211 Oncology and carcinogenesis